News | July 27, 2021
Alembic Pharmaceuticals Q1FY22 net slides to Rs. 164.52 Cr
The US business faced price erosion due to increased competition.
The US business faced price erosion due to increased competition.
Winlevi has been approved by the United States FDA as a novel drug with a unique mechanism of action for the topical treatment of acne in patients 12 years and older
The company posted net loss of Rs.56.69 crores for the period ended June 30, 2020.
The company is confident of commencing production at both Mahad and Chiplun units soon
The company proposes to utilise the net proceeds from the fresh issue towards payment of outstanding purchase consideration
It posted net (loss) of Rs.(34.13) crores for the period ended June 30, 2020.
State-of-the-art R&D lab expands technical feasibility capabilities for long-acting delivery of small molecules, biologics, nucleotides
The company has reported PAT of Rs. 10.7 crore for Q1 FY22, higher by 23% YoY
As of 2025, the new Translational Science Center will offer room for more than 500 scientists, who will conduct research in a wide variety of fields ranging from the identification of disease biomarkers to the development of targeted therapies
The company will engage with the agency to resolve the import alert at the earliest and ensure cGMP compliance.
Subscribe To Our Newsletter & Stay Updated
